This article is more than 5 years old. Information may no longer be current.
Inaugural ocular gene therapy meeting slated
The Future is Now: Leaders in Ocular Gene Therapy meeting will be held for the first time Wednesday, Oct. 9, preceding the American Academy of Ophthalmology meeting in San Francisco.
“In one afternoon, in a concentrated format, the audience will get an update on what is currently evolving in the field of ocular gene therapy,” course director Kourous A. Rezaei, MD, told Healio/OSN.
The non-CME event is presented in four sessions, with more than 30 speakers and panelists discussing adeno-associated virus manufacturing, regulatory, clinical trial endpoints, subretinal surgery, clinical trials in inherited retinal diseases, clinical trials in large indications, real-world experience, venture capital, “and the list goes on,” Rezaei said.
“Gene therapy may potentially revolutionize our field in the next decade. We may have the opportunity to offer cure to some of the inherited retinal diseases that currently lead to loss of vision. Further, one may be able to reduce the treatment burden of monthly injections with a single gene therapy procedure,” Rezaei said.
The goal of the meeting, he said, “is to have a dedicated forum for the pioneer leaders, scientists and clinicians in the field of ocular gene therapy to discuss the most cutting-edge technologies currently being evaluated in clinical trials or commercially available.” – by Eamon Dreisbach
Reference:
Future is Now: Leaders in Ocular Gene Therapy meeting. oculargenetherapy.com. Accessed Oct. 4, 2019.
Disclosure: Rezaei reports he is chief medical officer for Iveric bio, associate professor at Rush University Medical Center and partner at Illinois Retina Associates.